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Abstract: Thymic malignancies are rare tumors of the mediastinum.
c-KIT is highly expressed in thymic carcinomas (TC) but infre-
quently in thymomas. Anecdotal experience suggests activity of
imatinib mesylate in TC. Patients with unresectable World Health
Organization B3 thymomas or TC, performance status 0 to 2, good
organ function, and measurable disease were enrolled in this study.
Imatinib was administered at 600 mg PO daily. Seven patients were
recruited at one institution: two World Health Organization B3
thymomas and five TC. Imatinib treatment was generally well
tolerated. Two patients had stable disease and five progressed.
Median survival was 4 months, and median time to progression was
2 months. c-KIT expression was found in one of four samples by
immunohistochemistry. No mutations were detected in the c-KIT or
PDGFRA genes in three samples analyzed. Imatinib has no major
activity in this rare tumor. Given the small number of patients
treated in this study, selection based on presence of c-KIT mutations
might be warranted.
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Thymomas are rare malignancies of the anterior superiormediastinum and represent 0.2 to 1.5% of all malignancies.1
The World Health Organization (WHO) histologic clas-
sification reports a continuum of tumors from A to C.2 Thymic
carcinomas (TC) (WHO type C) represent less than 1% of
thymic malignancies and seem to have a different molecular and
clinical profile compared with thymomas.3 In recent years,
studies on molecular alterations in thymic malignancies have
been published. c-KIT positivity by immunohistochemistry
(IHC) has been observed in 73 to 86% of TC.4,5
Imatinib mesylate inhibits several receptor tyrosine
kinases that are believed to play a role in the proliferation of
tumor cells including those associated with Bcr-Abl, PDGFR,
and c-KIT. Striking activity has been observed with imatinib
in chronic myelogenous leukemia6 and gastrointestinal
stroma cell tumors (GIST).7,8
We performed this study to evaluate response of high-
grade thymic malignancies known to overexpress c-Kit to
imatinib mesylate.
PATIENTS AND METHODS
Patients
This was an open-label phase II trial, to test the clinical
activity and safety of imatinib in patients with TC. Because of
the rarity of TC known to overexpress c-Kit, WHO B3
thymomas were also included in this study. Other inclusion
criteria were age more than 18 years, presence of measurable
and/or evaluable disease (by WHO Response Criteria), per-
formance status 0 to 2 (Eastern Cooperative Oncology
Group), adequate end organ function (total bilirubin 1.5 
upper limit of normal [ULN], serum glutamic oxaloacetic
transaminase and serum glutamic pyruvic transaminase
2.5  ULN, creatinine 1.5  ULN, absolute neutrophil
count1.5 109/L, platelets100 109/L, and leukocytes
3  109/L), and life expectancy more than 3 months.
Written informed consent was obtained.
Patients were treated with imatinib (supplied by Novartis,
Basle) 600 mg by mouth once a day. The dosage was increased
to 800 mg/d (400 mg twice daily) if there was evidence of
objective progression. The maximum duration of treatment
was 12 months. Beyond this period, treatment was to be
continued at the discretion of the investigator. In case of
toxicity, dose adjustments were made according to previously
reported guidelines.8 If treatment was interrupted for 14
days, then therapy was discontinued. Tumor response was
evaluated according to WHO response criteria. Patients with
nonmeasurable (but evaluable) disease were evaluated only in
terms of time to progression (TTP) and overall survival.
Toxicity was evaluated according to the National Cancer
Institute Common Toxicity Criteria version 2.0.
Before implementing this study, all necessary approv-
als were obtained from the Institutional Review Board/Inde-
pendent Ethics Committee.
Expression and Mutation Analysis
Histologic samples were used for IHC to test expres-
sion of c-KIT. Expression was assessed as described previ-
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ously9 and was based on conventional hematoxylin and eosin
stains and indirect immunoperoxidase stains for CD117
(polyclonal, 1/250; DAKO, Glostrup, Denmark). The CD117
immunostaining was performed without antigen retrieval, and
the presence of mast cells served as an internal control. IHC
results were reported as positive/negative.
Sequencing of the hot spots for mutations was per-
formed for c-KIT and PDGFRA genes. Tumor DNA was
isolated from formalin-fixed paraffin-embedded material.
DNA was isolated as described earlier.10 Exon 9, 11, 13, and
17 of the c-KIT gene and exon 12 and 18 of the PDGFRA
gene were amplified by polymerase chain reaction (PCR)
using the primers listed in Table 1. The PCR products were
purified (Qiaquick PCR purification KIT, Qiagen, The Neth-
erlands) and screened for mutations by bidirectional sequence
analysis, using the forward and reverse PCR primers.
Statistical Considerations
The primary end point of this study was to assess
response rate, and secondary end points were assessment of
safety, TTP, and overall survival. The Simon optimal design
was used. The accrual goal for the first stage of the trial was
14 patients.
RESULTS
Between June 2005 and August 2006, seven patients
with progressive disease and a median age of 67 years (range
36–76) were enrolled from one institution. Three patients
who were either elderly or refused chemotherapy received
imatinib as first-line therapy. Accrual was stopped after no
responses were seen in these patients, and the results of
mutation analysis did not confirm presence of mutations in
our study and in other series. Survival data has been updated
in April 2009. Patient characteristics and treatment outcome
are summarized in Table 2.
Toxicity
Five patients did not report side effects, or they re-
ported only grade 1 nausea or edema. One patient had grade
4 vomiting, which required interruption of treatment twice
until progression (no. 1). Another patient (no. 2) developed
grade 3 depression, associated with grade 2 asthenia and
requested interruption of treatment when no response was
documented at first computed tomography evaluation.
Responses and Survival
All five patients with TC had rapid disease progression
and have died; the two patients with WHO B3 thymomas had
stable disease and are still alive. One of these patients
subsequently received carboplatin-etoposide, which induced
a minor response, followed by radical resection of the tumor.
Seventeen months after surgery, the patient had a locore-
gional recurrence that was irradiated; the patient is still alive
with disease more than 38 months from initiation of imatinib.
The other patient stayed on imatinib for two cycles and on
progression received pemetrexed and then radiation therapy;
he is still alive with disease after more than 35 months from
start of imatinib. Median TTP was 2 months and median
survival was 4 months for all patients. Patients with B3
thymoma survived significantly longer than patients with TC
(p  0.037).
Immunohistochemistry and Mutation Analysis
Tumor samples could be retrieved from only four
patients for molecular analysis. IHC revealed some positivity
in one case of B3 thymoma, but was negative in the other
patient with B3 thymoma and in two TC (Table 3). Mutation
analysis failed in one of the four cases tested. No mutations
could be detected in any of the exons of c-KIT or PDGFRA
in the other three cases.
DISCUSSION
In this prospective study, no responses were seen with
imatinib therapy in two patients with WHO B3 thymoma and
five patients with TC and progressive disease at study entry.
No mutations were detected in c-KIT and PDGFRA genes in
three cases where they could be assessed.
The KIT gene belongs to the family of class III receptor
tyrosine kinases, which also includes the platelet derived growth
factor receptors alpha and beta (PDGFRA and PDGFRB). Over-
expression of KIT is seen in a variety of human tumors.
However, apart from GISTs, activating mutations of the KIT
and PDGFRA genes are uncommon in the majority of human
solid tumors.11
A large proportion of TCs (but not thymomas) show
immunohistochemical expression of KIT. Strobel et al.12
have described a case of epidermoid carcinoma of the thymus
with strong expression of KIT, an activating mutation in exon
11 of the KIT gene (V560del) and a response to imatinib that
lasted 6 months.
Pan et al.5 found immunohistochemical expression of
KIT in 19 of 22 cases (86%) of TC but no expression in 110
thymomas or 16 non-neoplastic thymus glands. They also
found no c-KIT mutations in exons 9, 11, 13, and 17 of the
KIT gene in 21 of 22 cases of TC by direct DNA sequencing.
TABLE 1. Primers Used for the Sequencing of c-KIT and PDGFRA Genes
Gene Exon Forward Primer Reverse Primer Product Size
c-KIT 9 AGTGCATTCAAGCACAATGG TGGTAGACAGAGCCTAAACATCC 151
c-KIT 11 CTCCAGAGTGCTCTAATGACTGA TGTTATGTGTACCCAAAAAGGTG 248
c-KIT 13 CATCAGTTTGCCAGTTGTGC CAGCTTGGACACGGCTTTAC 182
c-KIT 17 TGGTTTTCTTTTCTCCTCCAA TGCAGGACTGTCAAGCAGAG 185
PDGFRA 12 CCAGTTACCTGTCCTGGTCAT GGAGGTTACCCCATGGAACT 183
PDGFRA 18 TTCCTTTTCCATGCAGTGTG GACCAGTGAGGGAAGTGAGG 165
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Tsuchida et al analyzed KIT expression in 20 cases of
thymoma and 17 cases of TC. KIT expression by IHC was
seen in 11 cases of TC (all squamous cell carcinomas) and 0
thymomas. No mutations of c-KIT exons 9, 11, 13, and 17
were found in nine cases of TC that were tested.13
Yoh et al.14 analyzed 24 cases of thymoma and 17 cases
of TC and found KIT protein expression by IHC in 88% of
TC and 0% of thymomas. In 22 cases of thymoma and 11
cases of TC analyzed for mutations of exons 9, 11, 13, and 17
of the KIT gene, only one case of TC harbored a missense
mutation in exon 11 (L576P).
The presence of mutations in the c-KIT gene determines
response to imatinib therapy. In GIST, response rates in
patients who harbor mutations in exon 11, exon 9, and those
who lack detectable mutations are more than 80, 48, and 0,
respectively.7 A phase II study of imatinib at a dose of 400
mg twice daily in 21 patients with metastatic melanoma
showed one partial response in a patient with a tumor that
displayed a three base pair deletion in exon 15.15
Results of another small study of imatinib in patients
with TC were reported by Salter et al.16 Eleven patients with
advanced, unresectable, previously treated TC that was pos-
itive by IHC for c-KIT (nine cases) or PDGFR (two cases)
were treated with imatinib at a dose of 600 mg by mouth daily
on a 21-day cycle. No objective responses were observed.
Tumor samples were not analyzed for the presence of muta-
tions in the KIT gene.
A recent report (W. Pao, personal communication)
identified two KITmutations in six resected TC analyzed, one
of which is a novel mutation. The potential use of more
sensitive methods for mutation analysis may be of interest,
and it is conceivable that a small percentage of TCs may
harbor KIT mutations.
In summary, imatinib does not seem to have activity
in TCs. The rarity of KIT mutations in this disease may be
the reason for this negative result. Selection of patients
with TC harboring KIT mutations may be of interest for
further studies.
TABLE 2. Patient Characteristics and Outcome
Patient
No Gender
Age,
yr Previous Therapy Stage Histology PS Response Toxicity
TTP
(m) Following Therapy
Survival
(m)
1 M 36 VIP (NC) IVB liver
bone
Thymus carcinoma 2 NE/PD Vomiting grade 4 1 None 2
2 M 67 Debulking; RT;
metastasectomy;
carboplatin-
gemcitabine
(NC)
IVA pleura B3 1 NC Asthenia grade 2,
rash grade 1,
depression
grade 3
8 Pemetrexed (NC); RT 35
3 M 47 VIP (PR) Locoregional
relapse
(IVA)
B2/3 1 NC None 9a Carboplatin-etoposide
(MR); radical
resection
38
4 M 76 No IVB lung Thymus carcinoma 1 PD Nausea grade 1 2 Carboplatin-etoposide
(PR); RT
22
5 M 36 CAP IVB bone Thymus carcinoma 2 PD Nausea grade 1,
edema grade 1
2 None 4
6 M 71 No IVB
pericardium
bone
Thymus carcinoma 2 PD Nausea grade 1 1 None 1
7 F 69 No IVB lung,
neck
lymphnodes
Thymus squamous
carcinoma
2 PD None 0.5 Carboplatin-etoposide
(PD)
2
aTTP censored; patient underwent further chemotherapy followed by resection, in absence of progression on imatinib.
NC, no change; PR, partial response; PD, progressive disease; RT, radiotherapy; VIP, etoposide, ifosfamide, cisplatin; CAP, cyclophosphamide, doxorubicin, cisplatin; TTP, time
to progression; MR, minor response.
TABLE 3. Results of c-Kit Immunohistochemistry and Mutation Analysis of c-KIT and
PDGFRA Genes
Patient No Histology Kit Immunohistochemistry Kit Mutations PDGFRA Mutations
1 Thymus carcinoma ND ND ND
2 B3 15% cells positive None None
3 B2/3 Negative Failed Failed
4 Thymus carcinoma ND ND ND
5 Thymus carcinoma ND ND ND
6 Thymus carcinoma Negative None None
7 Thymus squamous carcinoma Negative None None
ND, not done.
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